Pulse Biosciences Past Earnings Performance
Past criteria checks 0/6
Pulse Biosciences has been growing earnings at an average annual rate of 1.9%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 7.3% per year.
Key information
1.9%
Earnings growth rate
19.8%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 7.3% |
| Return on equity | -58.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
May 16We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
May 10
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO
Sep 20Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Pulse Biosciences gets Health Canada approval for CellFX System
Jun 09Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
Feb 24Pulse Biosciences establishes at-the-market equity program
Feb 04What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?
Jan 20Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication
Jan 12Revenue & Expenses Breakdown
How Pulse Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -46 | 19 | 29 |
| 30 Jun 24 | 0 | -44 | 17 | 29 |
| 31 Mar 24 | 0 | -43 | 16 | 29 |
| 31 Dec 23 | 0 | -42 | 16 | 28 |
| 30 Sep 23 | 0 | -39 | 14 | 24 |
| 30 Jun 23 | 0 | -47 | 16 | 21 |
| 31 Mar 23 | 0 | -51 | 20 | 20 |
| 31 Dec 22 | 1 | -59 | 26 | 21 |
| 30 Sep 22 | 2 | -65 | 32 | 22 |
| 30 Jun 22 | 2 | -61 | 35 | 24 |
| 31 Mar 22 | 2 | -62 | 34 | 26 |
| 31 Dec 21 | 1 | -64 | 34 | 29 |
| 30 Sep 21 | 1 | -62 | 31 | 30 |
| 30 Jun 21 | 0 | -61 | 29 | 31 |
| 31 Mar 21 | 0 | -57 | 27 | 29 |
| 31 Dec 20 | 0 | -50 | 24 | 26 |
| 30 Sep 20 | 0 | -50 | 24 | 26 |
| 30 Jun 20 | 0 | -49 | 24 | 25 |
| 31 Mar 20 | 0 | -49 | 24 | 25 |
| 31 Dec 19 | 0 | -47 | 23 | 25 |
| 30 Sep 19 | 0 | -42 | 19 | 23 |
| 30 Jun 19 | 0 | -41 | 19 | 22 |
| 31 Mar 19 | 0 | -39 | 19 | 20 |
| 31 Dec 18 | 0 | -38 | 20 | 17 |
| 30 Sep 18 | 0 | -37 | 22 | 15 |
| 30 Jun 18 | 0 | -34 | 21 | 13 |
| 31 Mar 18 | 0 | -31 | 20 | 11 |
| 31 Dec 17 | 0 | -26 | 16 | 10 |
| 30 Sep 17 | 0 | -20 | 11 | 8 |
| 30 Jun 17 | 0 | -15 | 8 | 7 |
| 31 Mar 17 | 0 | -11 | 4 | 6 |
| 31 Dec 16 | 0 | -10 | 3 | 6 |
| 30 Sep 16 | 0 | -8 | 2 | 5 |
| 30 Jun 16 | 0 | -6 | 2 | 4 |
| 31 Mar 16 | 0 | -4 | 2 | 3 |
| 31 Dec 15 | 0 | -3 | 2 | 2 |
| 30 Sep 15 | 0 | -2 | 1 | 2 |
Quality Earnings: PLSE is currently unprofitable.
Growing Profit Margin: PLSE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PLSE is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.
Accelerating Growth: Unable to compare PLSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PLSE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: PLSE has a negative Return on Equity (-58.3%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 15:41 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pulse Biosciences, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Anthony Vendetti | Maxim Group |
| Christopher Cooley | Stephens, Inc. |